Vinpocetine in Patients With Parkinsonian Disease

Tanta University

Status and phase: Enrolling; Phase 3; Phase 2

Conditions: Parkinson Disease

Treatments: Drug: Vinpocetine; Drug: Levodopa Carbidopa

Study type: Interventional

Funder types: Other

Identifiers

NCT07229664

5469

Details and patient eligibility

About

The clinical manifestations of Parkinson's disease (PD), a chronic neurodegenerative condition, include resting tremor, hypokinesia, bradykinesia, stiffness and postural instability. These motor symptoms are caused by a selective loss and degeneration of dopaminergic neurons in the substantia nigra pars compacta (SNpc) region, which leads to a dopamine (DA) insufficiency in the striatum

Enrollment: 60 estimated patients

Sex: All

Ages: 50 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Age ≥ 50 years Both male and female will be included Negative pregnancy test and effective contraception. Diagnosed Parkinson's disease patient taking Levodopa

Exclusion criteria

Secondary causes of parkinsonism Patients taking anti-inflammatory drugs Atypical parkinsonian syndromes Prior stereotaxic surgery for Parkinson's disease Pregnancy and lactation Cardiovascular disease patients Patients with coagulation disorders Suffering from active malignancy Addiction to alcohol and / or drugs Known allergy to the studied medications

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

60 participants in 2 patient groups

Control group

Active Comparator group

Description:

Control group (Levo-dopa group, n =30) who will receive levodopa/carbidopa (125/12.5 mg) three times daily for 6 months

Treatment:

Drug: Levodopa Carbidopa

Vinpocetine group

Active Comparator group

Description:

Patients will receive levodopa/carbidopa (125/12.5 mg) three times daily plus vinpocetine 10 mg three times daily for 6 months

Treatment:

Drug: Levodopa Carbidopa

Drug: Vinpocetine